ArticleSignal transduction and targeted therapy2022
Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.
Open access · goldAbstract readPublished Erratum
In one paragraph
Article in Signal transduction and targeted therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 12 citations in OpenAlex.
- Disrupting MED8-dependent epigenetic reprogramming augments avapritinib sensitivity in PDGFRA-driven glioma.Journal of experimental & clinical cancer research : CR · 2026Article
- Augmenting the Anti-Leukemic Activity of the BCL-2 Inhibitor Venetoclax Through Its Transformation Into Polypharmacologic Dual BCL-2/HDAC1 and Dual BCL-2/HDAC6 Inhibitors.Drug development research · 2025Article
- Novel therapies upon failure of HMA plus venetoclax.Hematology. American Society of Hematology. Education Program · 2023Article
Corrections and comments
- Erratum for
Authors and funding
41 authors at 8 institutions in 4 countries.
Qi ZhangDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-7918-8952
Bridget Riley-GillisAbbVie Inc., North Chicago, IL, USA.
Lina HanDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yannan JiaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Alessia LodiDepartment of Nutritional Sciences, Department of Pediatrics, Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, TX, 78712, USA.
Haijiao ZhangDepartment of Cell, Developmental & Cancer Biology, Division of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Saravanan GanesanUniversité de Paris, Institut de la Recherche Saint-Louis (IRSL), Inserm Unit 1131, Paris, France.
Rongqing PanDana-Farber Cancer Institute, Boston, MA, USA.
Sergej N KonoplevDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shannon R SweeneyDepartment of Nutritional Sciences, Department of Pediatrics, Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, TX, 78712, USA.
Jeremy A RyanDana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-3327-1283
Yulia JitkovaPrincess Margaret Cancer Center, Toronto, ON, Canada.
Kenneth DunnerHigh Resolution Electron Microscopy Facility, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shaun E GrosskurthAbbVie Inc., North Chicago, IL, USA.
Priyanka VijayAbbVie Inc., North Chicago, IL, USA.ORCID http://orcid.org/0000-0002-6032-9081
Sujana GhoshAbbVie Inc., North Chicago, IL, USA.
Charles LuAbbVie Inc., North Chicago, IL, USA.
Wencai MaDepartment of Bioinformatics & Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Stephen KurtzDepartment of Cell, Developmental & Cancer Biology, Division of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Vivian R RuvoloDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Helen MaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Connie C WengDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Cassandra L RamageDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Natalia BaranDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-0618-4798
Ce ShiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Tianyu CaiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Richard Eric DavisDepartment of Lymphoma & Myeloma Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Venkata L BattulaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-5415-9058
Yingchang MiInstitute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Jing WangDepartment of Bioinformatics & Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Courtney D DiNardoDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michael AndreeffDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-1144-1958
Jeffery W TynerDepartment of Cell, Developmental & Cancer Biology, Division of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Aaron SchimmerDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Anthony LetaiDana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-1993-9013
Rose Ann PaduaUniversité de Paris, Institut de la Recherche Saint-Louis (IRSL), Inserm Unit 1131, Paris, France.
Carlos E Bueso-RamosDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Stefano TizianiDepartment of Nutritional Sciences, Department of Pediatrics, Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, TX, 78712, USA.
Joel LeversonAbbVie Inc., North Chicago, IL, USA.
Relja PopovicAbbVie Inc., North Chicago, IL, USA.
Marina KonoplevaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. mkonople@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USAbbVie (United States) · USDana-Farber Cancer Institute · USOregon Health & Science University · USThe University of Texas at Austin · USInserm · FRChinese Academy of Medical Sciences & Peking Union Medical College · CNPrincess Margaret Cancer Centre · CA
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.